Drug for primary progressive MS licensed in the USA
Ocrelizumab (Ocrevus) has become the first medicine to be licensed for primary progressive multiple sclerosis by the FDA (Food and Drug Administration), the American drug regulators. The FDA has also licensed ocrelizumab as a treatment for relapsing remitting MS.
Ocrelizumab is currently being assessed for drug licensing by the EMA (European Medicines Agency) for both relapsing remitting and primary progressive MS. It will then be appraised for cost and effectiveness as an NHS treatment for both types of MS. If these steps are successful ocrelizumab could be available on the NHS by 2018 at the earliest. The FDA decision does not affect the European assessment.
Pam Macfarlane, Chief Executive of the MS Trust commented:
"This is an encouraging step forward for people with PPMS in the USA. Though the UK is part of a separate licensing process in Europe and there is still a long way to go, the FDA decision is a cause for optimism. The MS Trust will keep watching how things are developing here and provide updates when we can. We are well aware how important this new medicine could be for people with PPMS."
About ocrelizumab
Ocrelizumab is taken as an intravenous infusion (drip) every six months. It reduces the number of B cells, a type of white blood cell, or lymphocyte thought to be involved in the abnormal immune response that attacks the myelin coating of nerve cells.
- In primary progressive MS, people taking ocrelizumab were 24% less likely to have an increase in their disability than those taking placebo
- In relapsing remitting MS, ocrelizumab reduced relapse rates by approximately 50% compared to beta interferon
- Infusion-related reactions, chest infections and herpes (oral herpes and shingles) were more frequent in those taking ocrelizumab
- Neoplasms (abnormal growth of tissues which can be benign or malignant), including several cases of breast cancer, were reported more frequently in those taking ocrelizumab
Find out more
- Ocrelizumab
- Drugs in development
- Primary progressive MS
- Roche press release
- FDA press release
- Can ocrelizumab slow down disability in primary progressive MS - Research Update 30 January 2017


The ADAMS project
25/05/2022 - 00:00
Dr Benjamin Jacobs spoke to us about a new study on the genetics of MS in people from minority ethnic backgrounds which may eventually shed light on why MS can be more severe for Black and Asian people.


Roxy's journey to diagnosis
16/05/2022 - 00:00
Roxy talks about her MS journey and the importance of sharing her own experiences to ensure that others don’t face the same challenges when receiving a diagnosis.


Lis' MS journey: one woman and her bike
04/05/2022 - 00:00
In May 2022, Lis will be heading off on her 5,000 mile cycling challenge. She shares how the idea came about and discusses why the support of the MS Trust was invaluable following a multiple sclerosis diagnosis.

Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.